Literature DB >> 22571978

Insulin and sex interactions in older adults with mild cognitive impairment.

Brenna Cholerton1, Laura D Baker, Emily H Trittschuh, Paul K Crane, Eric B Larson, Matthew Arbuckle, Hector Hernandez Saucedo, Susan M McCurry, James D Bowen, Wayne C McCormick, Suzanne Craft.   

Abstract

Alzheimer's disease (AD) and other dementias are likely preceded by a protracted preclinical state. Thus, identification of biomarkers that signal potential points of intervention during this prodromal phase (during which patients are largely able to compensate for their cognitive deficits) is of paramount importance. Insulin is a pancreatic hormone with potent central nervous system effects, and insulin dysregulation has been implicated in the pathogenesis of both AD and vascular dementia. The aim of the current study was to determine whether circulating insulin differs as a function of mild cognitive impairment (MCI) diagnosis, and whether this relationship is mediated by sex and apolipoprotein E (APOE) genotype. A sample of 549 nondemented participants aged 65 and over from the Adult Changes in Thought community-based cohort underwent cognitive testing and blood draw to determine fasting levels of plasma insulin. Subjects were categorized as having normal cognitive functioning, amnestic MCI, or nonamnestic MCI. Results showed that the relationship between insulin and diagnostic category is moderated by sex, such that men with nonamnestic or amnestic MCI have higher fasting plasma insulin than cognitively normal men, while women with amnestic MCI have lower fasting plasma insulin than cognitively normal women. Exploratory analyses suggest that APOE ε4 genotype may further influence the relationship between sex and insulin. Future research will help determine whether insulin dysregulation results in differential effects on vascular function and AD pathology as a function of sex and/or APOE genotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571978      PMCID: PMC3798013          DOI: 10.3233/JAD-2012-120202

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  63 in total

1.  Mayo's Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Trail-Making Test, the Stroop Test, and MAE Controlled Oral Word Association Test.

Authors:  Brett A Steinberg; Linas A Bieliauskas; Glenn E Smith; Robert J Ivnik
Journal:  Clin Neuropsychol       Date:  2005 Sep-Dec       Impact factor: 3.535

2.  Mayo's older Americans normative studies: category fluency norms.

Authors:  J A Lucas; R J Ivnik; G E Smith; D L Bohac; E G Tangalos; N R Graff-Radford; R C Petersen
Journal:  J Clin Exp Neuropsychol       Date:  1998-04       Impact factor: 2.475

3.  Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.

Authors:  Lixia Zhao; Bruce Teter; Takashi Morihara; Giselle P Lim; Surendra S Ambegaokar; Oliver J Ubeda; Sally A Frautschy; Greg M Cole
Journal:  J Neurosci       Date:  2004-12-08       Impact factor: 6.167

4.  Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.

Authors:  Jeffrey M Burns; Robyn A Honea; Eric D Vidoni; Lewis J Hutfles; William M Brooks; Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-07-01

5.  Hyperinsulinemia and cardiovascular disease in elderly men: the Honolulu Heart Program.

Authors:  C M Burchfiel; D S Sharp; J D Curb; B L Rodriguez; R D Abbott; R Arakaki; K Yano
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-03       Impact factor: 8.311

6.  Cardiovascular risk factors and hyperinsulinemia in elderly men: the Honolulu Heart Program.

Authors:  C M Burchfiel; J D Curb; R Arakaki; R D Abbott; D S Sharp; B L Rodriguez; K Yano
Journal:  Ann Epidemiol       Date:  1996-11       Impact factor: 3.797

7.  Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.

Authors:  S Craft; S Asthana; G Schellenberg; M Cherrier; L D Baker; J Newcomer; S Plymate; S Latendresse; A Petrova; M Raskind; E Peskind; C Lofgreen; K Grimwood
Journal:  Neuroendocrinology       Date:  1999-08       Impact factor: 4.914

Review 8.  Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals.

Authors:  Gerald M Reaven
Journal:  Endocrinol Metab Clin North Am       Date:  2005-03       Impact factor: 4.741

Review 9.  Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle.

Authors:  H U Häring; H Mehnert
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

10.  Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men.

Authors:  S Kalmijn; E J Feskens; L J Launer; T Stijnen; D Kromhout
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

View more
  4 in total

Review 1.  Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

Review 2.  Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke.

Authors:  Vasileios-Arsenios Lioutas; Freddy Alfaro-Martinez; Francisco Bedoya; Chen-Chih Chung; Daniela A Pimentel; Vera Novak
Journal:  Transl Stroke Res       Date:  2015-06-05       Impact factor: 6.829

Review 3.  Interactions between the central nervous system and pancreatic islet secretions: a historical perspective.

Authors:  Denovan P Begg; Stephen C Woods
Journal:  Adv Physiol Educ       Date:  2013-03       Impact factor: 2.288

4.  Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.

Authors:  Amy Claxton; Laura D Baker; Charles W Wilkinson; Emily H Trittschuh; Darla Chapman; G Stennis Watson; Brenna Cholerton; Stephen R Plymate; Matthew Arbuckle; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.